Re: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma - Response

被引：0
|
作者：
Saad, F [1 ]
机构：
[1] CHU Montreal, Hop Notre Dame de Bon Secours, Urooncol Clin, Montreal, PQ H2L 4M1, Canada
来源：
JOURNAL OF THE NATIONAL CANCER INSTITUTE | 2003年 / 95卷 / 15期
关键词：
D O I：
10.1093/jnci/djg021
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1175 / 1175
页数：1
相关论文
共 50 条
  • [41] Survival benefit during zoledronic acid and docetaxel-based chemotherapy in metastatic hormone-refractory prostate cancer patients: an institutional report
    Samelis, G. F.
    Ekmektzoglou, K. A.
    Tsiakou, A.
    Giannakaki, S.
    Georgoulias, D.
    Christophilopoulos, K.
    JOURNAL OF BUON, 2011, 16 (04): : 738 - 743
  • [42] Economic Evaluation of Denosumab Compared with Zoledronic Acid in Hormone-Refractory Prostate Cancer Patients with Bone Metastases
    Xie, Jipan
    Namjoshi, Madhav
    Wu, Eric Q.
    Parikh, Kejal
    Diener, Melissa
    Yu, Andrew P.
    Guo, Amy
    Culver, Kenneth W.
    JOURNAL OF MANAGED CARE PHARMACY, 2011, 17 (08): : 621 - 634
  • [43] Randomized, double-blind, controlled trial of mitoxantrone/prednisone and Clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain
    Ernst, DS
    Tannock, IF
    Winquist, EW
    Venner, PM
    Reyno, L
    Moore, MJ
    Chi, K
    Ding, K
    Elliott, C
    Parulekar, W
    JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (17) : 3335 - 3342
  • [44] Normalization of serum PSA level using zoledronic acid on metastatic hormone-refractory prostate cancer resistant to estramustine and betamethasone
    Seike, Kensaku
    Asaeda, Yukiko
    Yamamoto, Naoki
    Maeda, Shinichi
    CENTRAL EUROPEAN JOURNAL OF UROLOGY, 2009, 62 (02) : 114 - 115
  • [45] Zoledronic acid is an effective treatment for osteoporosis in patients with thalassemia major: Results of a randomized, placebo-controlled, trial.
    Voskaridou, E
    Loukopoulos, D
    Stoupa, E
    Spyropoulou, E
    Meletis, J
    Terpos, E
    BLOOD, 2005, 106 (11) : 1017A - 1018A
  • [46] A phase II trial of gefitinib in patients with non-metastatic hormone-refractory prostate cancer
    Small, Eric J.
    Fontana, Joseph
    Tannir, Nizar
    DiPaola, Robert S.
    Wilding, George
    Rubin, Mark
    Iacona, Renee Bailey
    Kabbinavar, Fairooz F.
    BJU INTERNATIONAL, 2007, 100 (04) : 765 - 769
  • [47] Current clinical trial design issues in hormone-refractory prostate carcinoma
    Vogelzang, NJ
    Crawford, ED
    Zietman, A
    CANCER, 1998, 82 (11) : 2093 - 2101
  • [48] Phase II placebo-controlled randomized discontinuation trial of sorafnib in patients with metastatic renal cell carcinoma
    Ratain, Mark J.
    Eisen, Tim
    Stadler, Walter M.
    Flaherty, Keith T.
    Kaye, Stan B.
    Rosner, Gary L.
    Gore, Martin
    Desai, Apurva A.
    Patnaik, Amita
    Xiong, Henry Q.
    Rowinsky, Lric
    Abbruzzese, James L.
    Xia, Chenghua
    Simantov, Ronit
    Schwartz, Brian
    O'Dwyer, Peter J.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (16) : 2505 - 2512
  • [49] Economic evaluation of denosumab compared with zoledronic acid in patients with hormone-refractory prostate cancer with bone metastases.
    Yu, A. P.
    Namjoshi, M.
    Xie, J.
    Parikh, K.
    Wu, E. Q.
    Guo, A.
    Culver, K. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [50] Prospective randomized phase II trial of pegylated doxorubicin in the management of symptomatic hormone-refractory prostate carcinoma
    Heidenreich, A
    Sommer, F
    Ohimann, CH
    Schrader, AJ
    Olbert, P
    Goecke, J
    Engelmann, UH
    CANCER, 2004, 101 (05) : 948 - 956
12345